MSC patch with fetal myelomeningocele (MMC) surgery : a unique therapy to improve…
Validate targets, mechanisms and translational rationale before committing development resources.
Offer overview
What this offer helps you achieve
Validate targets, mechanisms and translational rationale before committing development resources.
Scientific and technical scope
Development of an adjuvant therapy to myelomeningocele fetal surgery using a patch of umbilical cord derived mesenchymal stromal cells in order to improve children’s motor function. Developped by Lucie Guilbaud Translational Phase : In utero treatment of myelomeningocele with allogenic umbilical cord-derived mesenchymal stromal cells in an ovine model. Curr Res Transl Med. 2022. doi: 10.1016/j.retram.2021.103314. Allogenic umbilical cord-derived mesenchymal stromal cells improve motor function in prenatal surgical repair of myelomeningocele: An ovine model study. BJOG. 2024. doi: 10.1111/1471-0528.17624. Epub 2023 Jul 26. PMID: 37492999. Safety and efficacy of human umbilical cord-derived mesenchymal stromal cells in fetal ovine myelomeningocele repair DOI: 10.1186/s13287-024-03991-y
Capabilities mobilised
Therapeutic areasTherapeutic target discovery
Application fields
Tissue reconstruction
Discuss this offer
Could this capability strengthen your R&D programme?
Present your scientific, technical or clinical need and identify the most relevant route to collaboration.
Continue exploring
Related expertise for your programme
Offers selected through shared capabilities, application fields or institute expertise.
